You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 281 JAVELIN Medley VEGF: phase 2 study of avelumab + axitinib in patients with previously treated non-small cell lung cancer (NSCLC) or treatment naive, cisplatin-ineligible urothelial cancer (UC)

Citation Tools

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials completed
281 JAVELIN Medley VEGF: phase 2 study of avelumab + axitinib in patients with previously treated non-small cell lung cancer (NSCLC) or treatment naive, cisplatin-ineligible urothelial cancer (UC)

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Galffy G, Lugowska I, Poddubskaya E, et al
281 JAVELIN Medley VEGF: phase 2 study of avelumab + axitinib in patients with previously treated non-small cell lung cancer (NSCLC) or treatment naive, cisplatin-ineligible urothelial cancer (UC)
Journal for ImmunoTherapy of Cancer 2020;8:doi: 10.1136/jitc-2020-SITC2020.0281